Send us a text

As International #NASHDay 2023 approaches on June 8th, Surfing NASH dedicates a session to explore what makes this year’s occasion incredibly important for patient advocacy and what we all can consider in preparation. Founder, President and Chief Executive Officer of the Global Liver Institute (GLI), Donna Cryer, shares her anticipations alongside Pamela Danagher (Terns Pharmaceuticals) and co-hosts Jörn Schattenberg and Roger Green.

In this final session, Donna has departed and the remaining panelists propose ways by which to we can “step up” for this year’s #NASHDay. Jörn notes the benefit of early planning to prepare promotion and engagement within his own clinic and the various professional societies. Roger suggests obesity to be an intertwined area of focus important to include in #NASHDay activities. From an industry perspective, Pam is interested in working with the assistance and collaboration of regulatory authorities to create drug development pathways that are simpler, faster, less invasive and minimize the need for any unnecessary biopsies. Roger states that the way we envision the future is limited by biopsy in terms of the definition of what efficacy is and how to conduct clinical trials. For him, a big step up for all is to adopt a bold and expansive view of how the world is going to change and to anticipate with proactivity.

If you enjoy the episode, have questions or interest around its contents and Fatty Liver disease, we kindly ask that you submit reviews wherever you download our discussions. Further, if you have questions or interest around participating in #NASHDay 2023, please let us know your ideas by writing to [email protected].

Stay Safe and Surf On!